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Pediatric parapneumonic empyema (PPE) has been 
increasing in several countries including Spain. Strepto-
coccus pneumoniae is a major PPE pathogen; however, 
antimicrobial pretreatment before pleural ﬂ  uid (PF) sam-
pling frequently results in negative diagnostic cultures, 
thus greatly underestimating the contribution of pneumo-
cocci, especially pneumococci susceptible to antimicrobial 
agents, to PPE. The study aim was to identify the sero-
types and genotypes that cause PPE by using molecular 
diagnostics and relate these data to disease incidence 
and severity. A total of 208 children with PPE were pro-
spectively enrolled; blood and PF samples were collected. 
Pneumococci were detected in 79% of culture-positive and 
84% of culture-negative samples. All pneumococci were 
genotyped by multilocus sequence typing. Serotypes were 
determined for 111 PPE cases; 48% were serotype 1, of 3 
major genotypes previously circulating in Spain. Variance 
in patient complication rates was statistically signiﬁ  cant 
by serotype. The recent PPE increase is principally due 
to nonvaccine serotypes, especially the highly invasive 
serotype 1.  
P
leural effusions occur in at least 40% of children hos-
pitalized with bacterial pneumonia. Occasionally, the 
infectious agent invades the pleura to cause pediatric para-
neumonic empyema (PPE) (1), characterized by the pres-
ence of pus. Although rarely associated with fatalities in 
industrialized countries, PPE often results in prolonged 
hospitalization and surgical intervention, and patients are 
at risk for serious and long-lasting illness (2,3).
An increasing incidence of PPE has been reported in 
several countries since the mid-1990s (2–6), but it is not 
clear why. Streptococcus pneumoniae is the most fre-
quently found microorganism in most recent reports. How-
ever, conventional microbiologic culture methods have low 
sensitivity, usually because of antimicrobial pretreatment 
before sterile-site sampling. Consequently, the contribu-
tion of antimicrobial drug–susceptible serotypes might be 
higher than reported estimates. Molecular and antigen de-
tection-based techniques, including direct molecular typing 
of culture-negative pleural ﬂ  uid (PF) samples (7), can be 
useful adjuncts in deﬁ  ning the contributory role of differ-
ent microorganisms and pneumococcal serotypes to PPE 
etiology (4,8).
Our study’s goal was to prospectively investigate the 
molecular epidemiology of pneumococcal PPE among 
children admitted to 3 of the largest tertiary-care pediatric 
hospitals in Spain. There were 4 objectives: 1) identify 
the serotypes and multilocus sequence typing (MLST) 
genotypes causing PPE and determine whether a temporal 
change in the circulating genotypes could explain the re-
cent increase; 2) determine whether the causal genotypes 
were only associated with PPE or also caused other inva-
sive pneumococcal disease (IPD) in the same population, 
or were carried by healthy children; 3) compare serotypes 
and genotypes recovered from northern and southern 
Spain in the context of regional differences in 7-valent 
pneumococcal conjugate vaccine (PCV7) uptake; and 
4) identify any differences between highly invasive se-
rotypes and more opportunistic serotypes with respect to 
epidemiology and inﬂ  ammatory markers.
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Methods
Prospective and Retrospective Identiﬁ  cation 
of PPE Cases
PPE cases involving all children <18 years of age at 
Sant Joan de Deu Hospital Barcelona, Spain, were prospec-
tively enrolled beginning October 1, 2003. PPE patients 
<14 years of age admitted to Virgen del Rocío Children’s 
Hospital (VRCH) in Seville and Carlos de Haya Children’s 
Hospital (CHCH) in Malaga were prospectively enrolled 
beginning January 1, 2005. The study period extended 
to June 30, 2006, in all locations for molecular analyses 
and through December 2006 for trend analyses. Eligible 
patients were identiﬁ  ed through notiﬁ  cation by attending 
physicians or by clinical microbiology laboratories when a 
sterile site sample was pneumococcal culture or pneumo-
lysin (ply) positive. Participating centers served a pediatric 
referral population of 607,796 (9% of the corresponding 
Spanish population). 
PPE was deﬁ  ned according to published criteria (6). Re-
quirements for thoracocentesis, decortication, administration 
of ﬁ  brinolytics, and antimicrobial drug therapy were deter-
mined according to usual clinical practice. Patients with PPE 
not requiring thoracocentesis or surgical decortication were 
excluded, as were cases with PF analysis consistent with a 
transudate. Thoracocentesis was performed by pediatric sur-
geons, except for acutely ill patients who were tapped in the 
emergency department or intensive-care unit. PF specimens 
were sent for routine microbiologic culture and biochemi-
cal analysis; remaining ﬂ  uid was frozen at –80ºC for further 
molecular testing. Clinical, demographic, and outcome data 
were collected by using a standardized case report form. 
To identify temporal trends, we also retrospectively 
identiﬁ  ed PPE cases at VRCH and CHCH during 1998–
2004 using International Classiﬁ   cation of Diseases, 9th 
Revision, codes for empyema (510.0 or 510.9) and chart 
review. PPE deﬁ  nition and patient exclusion criteria were 
the same as those used in the prospective study.
Nasopharyngeal Carriage Study
From January 2005 through June 2006, nasopharynge-
al (NP) swab specimens were obtained from 635 children 6 
months to 6 years of age attending 4 primary healthcare cen-
ters for well-child visits and 2 hospital emergency rooms in 
Seville. Exclusion criteria were chronic medical condition, 
moderate to severe acute process including fever >39ºC, 
lower respiratory tract infection, vomiting, dehydration, or 
other ill appearance. The study was conducted according to 
World Health Organization recommendations (9) 
Informed Consent
Written informed consent was obtained from parents 
or legal guardians of participating children before thoraco-
centesis or nasopharyngeal swabbing. Hospital ethics com-
mittees approved the studies.
Retrospective Analysis of IPD Cases
IPD cases from patients at VRCH and CHCH during 
2001–2006 were retrospectively ascertained from microbi-
ology department databases of both centers and conﬁ  rmed 
by chart review. Viable pneumococcal isolates were sero-
typed (70% of cases) by the Spanish Reference Laboratory 
of Pneumococci and genotyped by MLST (61% of cases).
Testing of PF Samples
Pneumococci were identiﬁ  ed by using microbiologic 
and molecular genotyping methods; susceptibility testing 
was performed by agar dilution (10), and Clinical Labo-
ratory Standards Institute interpretive criteria were used 
to deﬁ  ne susceptibility (10). Culture-negative PFs were 
assayed for the presence of the pneumolysin (ply) gene, 
by using a real-time PCR in Barcelona adapted from Cor-
less et al. (11) and a published assay (12) in Seville. Con-
ventional serotyping using the Quellung method was per-
formed where possible; culture-negative or incompletely 
genotyped PFs were serotyped by using a real-time PCR 
that targets different capsular locus genes (13). DNA was 
extracted from PFs by using 20% wt/vol Chelex-100 resin 
(Bio-Rad Laboratories, Hercules, CA, USA) in Barcelo-
na and the Nucleospin kit (Clontech Laboratories, Inc., 
Mountain View, CA, USA) in Seville. 
Molecular Genotyping
MLST was performed by using standard methods 
(14), with the exception of a change in PCR primers for 
the gdh, recP, xpt genes when genotyping PFs directly; 
in the PCR ampliﬁ  cation step, ﬁ  rst-round primers from 
a nested PCR (15) were substituted for standard MLST 
primers to increase sensitivity. Allele and sequence type 
(ST) designations were made by using the MLST website 
(www.mlst.net).
Statistical Analyses
Statistical analyses were performed by using SPSS for 
Windows version 14.0 (SPSS, Inc., Chicago, IL, USA). Re-
ported p values were 2-tailed, and the level of signiﬁ  cance 
was set at 0.05. Analysis of categorical variables was per-
formed with the χ2 test and Fisher exact test, as appropriate. 
Continuous variables were compared by analysis of vari-
ance followed by a Bonferroni test for multiple compari-
sons. When data were not normally distributed, we used 
the Kruskal-Wallis test and conducted posterior compari-
son between individual groups using the Mann-Whitney U 
test with the Bonferroni correction. IPD potential was esti-
mated by using a standard odds ratio and Mantel-Haenszel 
conﬁ  dence intervals (16). 
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Results
Overall PPE Trends 
In Seville and Malaga, the annual number of PPE cases 
increased 13-fold (5 to 66 cases) during 1998–2006 (Figure 
1). In Barcelona, the annual number of PPE cases increased 
from 11 cases in 2004 to 62 cases in 2006 (data before Oc-
tober 2003 were not available). Over these study periods, 
no obvious changes in referral patterns, overall pediatric 
population, guidelines for evaluating children with fever, 
pneumonia or PPE, or recommendations for performing di-
agnostic thorachocentesis in children with PPE were found. 
Table 1 describes the demographic characteristics of the 
208 PPE patients prospectively enrolled during the molecu-
lar analysis study period (n = 98, Seville and Malaga; n = 
110, Barcelona). There were no deaths. 
Microbiologic Evaluation
Sixty-seven (32%) patients had positive blood and/or 
PF cultures for any pathogen, and S. pneumoniae was isolat-
ed from 53 (79%) of these cases (Figure 2). In 51 of these, a 
pneumococcal serotype could be identiﬁ  ed via the conven-
tional Quellung reaction. Evidence of pneumococcal infec-
tion in 99 (84%) of 118 culture-negative PF samples was 
found on the basis of ply or wzg gene detection. PPE cases, 
diagnosed only by ply or wzg PCR, were signiﬁ  cantly more 
likely to have received antimicrobial drug therapy before 
PF aspiration than patients with culture-positive pneumo-
coccal PPE (92% vs. 53%; p<0.0001). Of the 99 culture-
negative PF samples, 67 (65 ply-positive/wzg-positive and 
2 ply-negative/wzg-positive) had a sufﬁ  cient sample to en-
able serotype testing by PCR. In 52 of these samples, a se-
rotype could be identiﬁ  ed. Thus, a pneumococcal serotype 
was identiﬁ  ed in 103 PF samples (Figure 2). 
In addition, a predicted serotype based on MLST 
genotyping was established for 2 cases with negative PCR 
results and 6 cases for which neither conventional nor 
PCR-based serotyping was possible (Figure 2). Such pre-
dictions were possible because there is a strong relationship 
between serotype and MLST genotype for most genotypes 
(16–18; www.mlst.net), with the exception of a small num-
ber of well-known genotypes that are associated with dif-
ferent serotype variations. 
Eighty-one PF samples were fully genotyped, and 18 
were partially genotyped (>4 alleles), by MLST. An ST 
was identiﬁ  ed for 31 of the 99 culture-negative/ply-positive 
PPE. Among these 31 cases, there was full concordance 
between MLST data and PCR results for conﬁ  rmation of 
predicted serotypes (Figure 2). Eighteen PF samples were 
partially genotyped by MLST: 2 were presumptive sero-
type 1 pneumococci based on 5–6 loci matching ST228; 
1 was a presumptive serotype 5 based on 5 loci matching 
ST1223; 7 were genotyped at >4 loci and serotyped by 
PCR (serotype 1, n = 5; serotype 7F and 19A, n = 1 each); 
and 8 samples were partially genotyped at >4 loci (indicat-
ing presence of a pneumococcus), but PCR serotyping was 
either negative or not performed. Samples with predicted 
serotypes based on incomplete genotyping data were not 
included in further analyses.
Serotype Distribution
Ten serotypes were identiﬁ  ed among the 111 PPE cas-
es with tentatively assigned or conﬁ  rmed serotyping infor-
mation (Table 2). Non–PCV7 serotypes caused 96 (89%) 
cases of PPE, including serotype 1, which was detected in 
48% of the patient samples. Although a signiﬁ  cantly higher 
proportion of PPE was caused by 7F in Seville and Malaga 
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Figure 1. Annual number of pediatric parapneumonic empyema 
(PPE) cases among children <14 years of age admitted to 
Seville and Malaga hospitals from 1998 to June 2006 (combined 
prospective and retrospective data) and among children <18 years 
of age admitted to a Barcelona hospital from October 2003 through 
June 2006. *October 1, 2003, through December 31, 2003.
Table 1. Demographic characteristics of 208 patients with PPE 
enrolled during the molecular analysis study period* 
Characteristic Value
Age, mo, mean ± SD (range)  51.8 ± 31 
(2–180) 
Gender ratio, M/F  1.06
Underlying disease, %†  4
Oral antimicrobial drugs before admission, %‡  29
Antimicrobial drug free before thoracocentesis, %§   23
PCV7 >1 dose, %  31
Referral, %  38
*PPE, pediatric parapneumonic empyema; PCV7, 7-valent pneumococcal 
conjugate vaccine. 
†Underlying disease included (no. patients): lymphoma (2), congenital 
heart disease (2), mild psychomotor retardation (2), varicella zoster 
infection (2) and genetic disease (1).  
‡Median duration: 3 d, range 1–17 d.  
§100/147 children who had not been treated with oral antimicrobial drug 
therapy before admission received intravenous antimicrobial drug 
treatment before thoracocentesis for a median of 2 d (range 1–10 d). Pediatric Parapneumonic Empyema
than in Barcelona, the contribution of other serotypes by 
region was not signiﬁ  cantly different (Table 2). PCV7 up-
take among PPE patients was signiﬁ  cantly higher in Seville 
and Malaga than Barcelona (40% vs. 22%, p = 0.005), but 
there were no signiﬁ  cant regional differences in vaccina-
tion status among children infected with serotype 1 (28% 
vs. 22%, p = 0.63).
Eight (15%) of 53 cultured pneumococci were inter-
mediately penicillin resistant and 4 (8%) were resistant at 
high levels. Serotype 1, 3, 5, and 7F pneumococci were 
uniformly susceptible to penicillin and signiﬁ  cantly more 
common among culture-negative than culture-positive PF 
samples (89% vs. 71%, p = 0.02). 
Genotyping by MLST 
Eighty-one PF samples were fully genotyped; 26 STs 
were identiﬁ  ed (Table 3). Three of the major serotype 1 
STs (18), ST228, ST304 and ST306, were identiﬁ  ed, al-
though ST228 was only detected in Seville and Malaga, 
and ST304 only in Barcelona (Table 3). Serotypes 5 and 7F 
were represented by globally distributed genotypes ST289 
(Colombia5-19) and a closely related single-locus variant, 
ST1223; and ST191 (Netherlands7F-39), respectively. 
Six of 7 serotype 14–positive PF samples were ST156 
(Spain9V-3). Genotypic diversity among the serotypes in 
this study was greatest for serotype 19A; 5 unrelated STs 
were detected, including ST81 (Spain23F-1). Such variants 
of ST81 have also previously been detected.
IPD and Nasopharyngeal Carriage in 
Seville and Malaga
During 2001–2006, 180 cases of IPD involving chil-
dren <14 years of age were diagnosed with IPD at Seville 
and Malaga hospitals, and 126 isolates were available for 
serotyping; 110 of these isolates were also genotyped. 
Twenty-three percent (29/126) of all IPD was due to sero-
type 1. Over this period, there was a statistically nonsigniﬁ  -
cant increase in the proportion of IPD cases due to serotype 
1: 17% (2001–2003) vs. 27% (2004–2006), p = 0.19. 
Twenty-four serotypes were identiﬁ  ed; 10 serotypes 
caused both PPE and other IPDs (Table 4), and 14 sero-
types caused only other IPDs (6B, 11, 13, 15A, 16, 18C, 
22, 23A, 23B, 23F, 24, 33, 34, and 38). Serotype 1 iso-
lates were almost exclusively associated with pulmonary 
disease, including bacteremic pneumonia (12/29, 41%) 
and PPE (15/29, 52%). The 3 major serotype 1 PPE geno-
types were also found among this collection of serotype 1 
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208 pleural fluids evaluated by 
conventional microbiological culture 
67 culture-positive        141 culture-negative 
118 DNA extracts  
genotyped 
99 ply- and/or wzg-
positive 
51 serotyped 
by 
conventional 
methods      
52 serotypes identified by 
real-time PCR assay 
8 predicted serotypes 
by MLST genotype      
14 other 
microorganisms*    
67 samples analyzed  
by PCR† 
31 fully genotyped      50 fully genotyped      
53 Streptococcus 
     pneumoniae    
23 predicted serotype 
confirmed by real-
time PCR assay 
2 negative by 
real-time PCR 
assay            
6 not tested by 
real-time PCR 
assay            
18 partially genotyped‡     
Figure 2. Microbiologic characteristics of pleural ﬂ  uid specimens 
from pediatric parapneumonic empyema case-patients. *Strep-
tococcus pyogenes (6), Staphylococcus aureus (3), Mycobacterium 
tuberculosis (2), Escherichia coli (1), Streptococcus mitis (1), 
Peptostreptococcus spp. (1). †Pleural ﬂ   uids analyzed by PCR 
included 2 samples that were ply  negative but wzg positive. 
‡18 partially genotyped by multilocus sequence typing (MLST) 
(>3 alleles), as DNA concentration was too low for reliable PCR 
ampliﬁ  cation and sequencing.
Table 2. Pneumococcal serotypes identified among pleural fluid samples 
Serotype*  Barcelona, no. (%), n = 56  Seville/Malaga, no. (%), n = 55  Total, no. (%), n = 111  p value 
1 27 (48)  26 (47)  53 (48)  0.92
7F 3 (5)  11 (20)  14 (13)  0.02
3 5 (9)  7 (13)  12 (11)  0.56
5 6 (11)  3 (5)  9 (8)  0.28
14 4 (7)  5 (9)  9 (8)  0.74
19A 6 (11)  2 (4)  8 (7)  0.27
9V 2 (4)  0 2 (2)  0.50
6A 2 (4)  0 2 (2)  0.50
8 0 1 (2)  1 (0.9)  1
19F 1 (2)  0 1 (0.9)  1
*7-valent pneumococcal conjugate vaccine serotypes include 4, 6B, 9V, 14, 18C, 19F, 23F. Pleural fluid samples were collected in Barcelona from 
October 1, 2003, through June 30, 2006, and in Seville and Malaga from January 1, 2005, through June 20, 2006. Serotypes were determined by 
Quellung reaction or PCR testing or predicted based on complete multilocus sequence typing, as described in the text. Boldface represents a statistically 
significant result. RESEARCH
IPD isolates, although ST304 was no longer detected after 
2002 and ST306 was ﬁ  rst detected in 2003. A retrospec-
tive analysis of serotype 1 invasive isolates submitted to the 
Spanish National Reference Laboratory since 1990 showed 
ongoing circulation of ST228 and ST304, but ST306 was 
only detected once before 2000 (1998; unpub. data). 
Serotype 14 was the second most common IPD-caus-
ing serotype, with an overall prevalence of 17% (23% in 
2001–2003 and 12% in 2004–2006; p = 0.12). The major 
serotype 14 genotype (ST156) identiﬁ  ed in PF samples 
was also detected throughout the entire 2001–2006 period 
among carriage isolates and in culture-positive IPD cases, 
mainly causing pulmonary disease (Table 4). Ten (8%) 
cases of culture-positive IPD were due to serotype 7F, 9 of 
which were detected after 2004. ST191 was the only sero-
type 7F genotype in IPD and NP carriage. 
Serotype-Speciﬁ  c Differences in Clinical 
Epidemiology, Inﬂ  ammatory Markers, and Outcome
PPE-associated serotypes were divided into 3 groups: 
1) serotypes 1, 5, 7F, and 14, consistently associated with 
the highest estimates of serotype-speciﬁ  c high invasive dis-
ease potential (HIDP) (16,17,19); 2) serotype 3 alone; and 
3) serotypes 6A, 9V, 19A, and 23F, which have a low in-
vasive disease potential (LIDP) (16,17,19). Odds ratio es-
timates of invasive disease potential demonstrate as much 
as 60- to 120-fold variation between the most invasive (1, 
4, 5, 7, 14, 18C) and the least invasive (3, 6A, 15, 23F) 
serotypes/serogroups (16,19).
PPE cases with HIDP serotypes were older than those 
with LIDP serotypes (median ages 56 and 24 months, re-
spectively; p = 0.0001) (Table 5). Among HIDP PPE cases, 
74% were due to serotypes 1 (n = 53) and 5 (n = 9) and 
comprised children >36 months of age, whereas serotype 
14 (n = 9) only caused PPE in patients <36 months of age 
(data not shown; p = 0.0001). Serotype 3 PPE was associat-
ed with signiﬁ  cantly more complications than PPE caused 
by HIDP and LIDP serotypes combined (p = 0.004). No 
other characteristics differed signiﬁ  cantly  between  indi-
vidual groups (Table 5). 
Discussion
In this study, we used molecular techniques to sensi-
tively evaluate PPE epidemiology among a large number 
of patients in geographically diverse locations of Spain. 
There was evidence of pneumococcal infection in most 
of the culture-positive and culture-negative cases of PPE, 
which was mainly associated with nonvaccine serotype 1 
followed by 3, 5, 7F, and 19A, as well as vaccine serotype 
14. Serotypes 1, 3, and 14 in particular are well-known 
PPE-associated serotypes (2,4,7,20,21). Antimicrobial 
drug–susceptible serotypes 1, 3, 5, and 7F were overrep-
resented in culture-negative PF samples, pointing to an 
important potential bias in PPE surveillance when surveil-
lance is based solely on conventional microbiologic cul-
ture methods. Infection with serotype 3 was a risk factor 
independently associated with PPE complications, a ﬁ  nd-
ing also seen in a US study (22).
Serotype 1 has also been the most prevalent IPD sero-
type among Spanish children <14 years of age, represent-
ing 5%, 11%, and 27% of all culture-positive pediatric IPD 
isolates sent to the Pneumococcal Reference Laboratory 
in 1997, 2003, and 2006, respectively (23). However, the 
increase in serotype 1 disease cannot easily be explained 
by a vaccine effect, in part because PCV7 coverage was 
relatively low in both regions for much of the study period. 
Registered in Spain in June 2001, PCV7 had a low initial 
uptake that increased to a reported coverage of 34%–45% 
in 2004–2005 (24,25).
In addition, increased PPE incidence largely caused by 
serotype 1 was reported in the United States and the United 
Kingdom in the decades before PCV7 introduction in 2000 
and late 2006, respectively (4,6,20). Previous studies have 
suggested that the high year-to-year variability of serotype 
1 and 5 disease may represent large-scale outbreaks of a 
cyclical nature (26–28). 
However, the observation in this study that 2 of the 3 
MLST genotypes of serotype 1 (ST228 and ST304) had 
been “resident” in Spain at least since 1990 indicates that 
serotype 1 PPE increases in Spain were likely not due to a 
recent introduction of a speciﬁ  c clone. In general, MLST 
analyses demonstrated that the recent increase in PPE was 
mainly due to pneumococcal STs previously described to 
be present in Spain and other European countries for some 
years (18,27,29–31).  
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Table 3. Sequence types and serotypes among 81 pneumococci 
detected in pleural fluid  
Serotype*  Total Sequence type (n) 
1 43 306and SLVs (23)† , 228 (11)‡, 
304and SLVs (8)†§, 2373 (1) 
5 9 289and SLV (9)† 
3 8 180 (5), 260 (2), 2590 (1)§ 
14 7 156 (6), 17 (1)§ 
19A 6 276 (2), 81 (1)§, 202 (1)§,  
1201 (1)‡, 2013 (1)§ 
7F 4 191 (4)
6A 2 135 (1)‡, 2377 (1)§ 
9V 2 838 (2)§ 
*Included are 8 strains that were culture and PCR negative, or not 
serotyped, but whose full genotyping by multilocus sequence typing 
(www.mlst.net) enabled serotypes 1, 5, and 7F to be predicted. These 
serotypes were predicted because in each case the sequence type (ST) 
was identical or closely related to a known genotype for serotypes 1, 5 or 
7F that have never been identified with anything other than those 
respective serotypes. These included ST (no.): 306 (2), 228 (1), 2373 (1), 
2378 (1), 2561 (1), 1223 (1), and 191 (1).  
†SLV, single locus variant (i.e., differs at only 1 MLST locus and thus is a 
closely related genotype). Major serotypes 1 and 5 ST groups included 
(no.  strains): ST306 (18) and SLVs 2375, 2376, 2378, and 2561 (1 each); 
ST304 (5) and SLVs 2374 (2), 2371 (1); ST289 (5), and SLV 1223 (4).  
‡Recovered only in Sevilla/Malaga.  
§Recovered only in Barcelona. Pediatric Parapneumonic Empyema
Our study has several limitations. First, the limited 
study period did not enable a longer-term analysis of PPE 
epidemiology. Second, our analyses relied exclusively on 
serotype identiﬁ  cation and MLST genotyping, neither of 
which detects differences in virulence factors apart from 
the serotype. Genetic factors independent of the capsule 
have been associated with invasiveness and disease sever-
ity (17,32,33). Third, other factors that may also modulate 
the epidemiology of PPE (e.g., differences in case ascer-
tainment between the retrospective and prospective studies, 
viral infections, or climatic patterns [34]) were not evaluat-
ed. Fourth, it remains difﬁ  cult to evaluate the PCV7 impact 
because reliable written immunization registries detailing 
the number of administered doses are lacking, and thus 
vaccine coverage ﬁ  gures mainly come from parent report-
ing. Finally, the results obtained here may not apply to less 
severe pneumonia cases, whose etiology may be qualita-
tively different. 
Unfortunately, PCV7 has a serotype coverage of only 
11%–14% (including the cross-reactive 6A) in the popula-
tion of PPE patients. However, conjugate vaccines contain-
ing serotypes 1, 5, and 7F, such as the newly developed 
10-valent pneumococcal Haemophilus inﬂ  uenzae protein 
D conjugate vaccine candidate (35), could increase the 
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Table 4. Contribution of PPE-associated serotypes and STs to IPD, Seville and Malaga, 2001–2006, and nasopharyngeal carriage in
children <6 years of age, Seville*† 
Serotype 
No. (%) patients with 
IPD, n = 126 
STs detected: diseases detected 
(no. patients), n = 111 
Carriage, no. (%) 
patients, n = 194 
STs detected in carriage 
(no. patients)  OR (95% CI) 
1 29 (23) 228: P (7), PPE (6), A (1), B (1)  1 (1)  306 (1)  57.7 (7.7–429.9)
306‡ : PPE (7), P (3)
304§: PPE (1)
14 22 (17) 156: P (7), PPE (4), M (2)  15 (8)  156 (12)  2.5 (1.3–5.1)
9: PPE (1) 409 (1)
62: P (1) 1684 (1)
124: PPE (1) 2607 (1)
2204: M (1)
7F 10 (8) 191: PPE (4), P (3), M (1), B (1)  3 (2)  191 (3)  5.5 (1.5–20.3)
19A 10 (8) 276: PPE (2), M (2), P (1)  13 (7)  276 (2)  1.2 (0.5–2.8) 
202: B (1)  202 (3) 
1201: PPE (1)  1201 (1) 
199 (2)
433 (2)
392 (1)
2109 (1) 
2609 (1) 
36 ( 5 ) 260: PPE (1), P (1), M (1)  7 (4)  180 (3)  1.6 (0.5–4.6) 
180: PPE (1)  260 (2) 
2200 (2) 
6A 5 (4)  1150: M (1)  24 (12)  338 (8)  0.29 (0.1–0.79)
1668: S (1)  386 (5) 
1876: M (1)  1876 (3) 
224 (2)
327 (1)
392 (1)
448 (1)
473 (1)
2201 (1) 
2611 (1) 
53 ( 2 ) 289: PPE (2)  2 (1)  289 (1)  2.3 (0.39–14.2) 
1223: P (1)  1540 (1)
19F 3 (2)  87: C (1), B (1)  8 (4)  81 (3)  0.57 (0.15–2.2) 
88: M (1) 87 (1)
179 (2)
63 (1)
2615 (1) 
9V 1 (1) 838: B (1)  3 (2)  838 (3)  0.5 (0.05–5) 
8 1 (1)  53: M (1)  0  – 
*Culture-positive isolates only for IPD. Boldface indicates a statistically significant result and represents STs that were identified among pleural fluids 
during the study period in Seville, Malaga, and Barcelona. An OR demonstrating the potential for each serotype to cause invasive disease, relative to its 
prevalence in nasopharyngeal carriage, was also calculated (16). Serotypes 6A, 19F, and 9V were associated with PPE in Barcelona (but not Seville and 
Malaga) and are included here for a complete list of invasive serotypes with any association to PPE among the 3 locations; however, data presented here 
are only from Seville and Malaga. Serotypes identified in IPD cases but not among children with PPE: 6B, 11, 13, 15A, 16, 18C, 22, 23A, 23B, 23F, 24, 
33, 34, 38. 
†PPE, pediatric parapneumonic empyema; IPD, invasive pneumococcal disease; ST, sequence type; OR, odds ratio; CI, confidence interval; A, arthritis; 
B, occult bacteremia; P, pneumonia; M,  meningitis; S, sepsis; C, orbital cellulitis.  
‡First detected in 2003.  
§First detected in 2002. RESEARCH
serotype coverage for PPE up to 80%; the subsequent addi-
tion of serotypes 3 and 19A in vaccine candidates currently 
in development would add an additional 18% of coverage 
(35). Finally, continued epidemiologic surveillance with 
molecular diagnostic techniques will be crucial to under-
standing this serious pediatric disease.  
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